Publication Name	World Journal of Clinical Cases
Manuscript ID	75093
Country	China

Received	2022-01-16 03:00
Peer-Review Started	2022-01-16 03:01
To Make the First Decision
Return for Revision	2022-03-16 00:33
Revised	2022-04-12 14:53
Second Decision	2022-06-20 03:04
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-06-26 22:52
Articles in Press	2022-06-26 22:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-07-21 12:20
Publish the Manuscript Online	2022-08-01 09:20

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Tian-Tian Xuan, Guang-Yi Li, Si-Bo Meng, Zhan-Mei Wang and Lin-Li Qu
ORCID	Author(s) ORCID Number Tian-Tian Xuan http://orcid.org/0000-0002-4616-7514 Guang-Yi Li http://orcid.org/0000-0002-0203-340X Si-Bo Meng http://orcid.org/0000-0003-1861-496X Zhan-Mei Wang http://orcid.org/0000-0002-7091-6052 Lin-Li Qu http://orcid.org/0000-0001-5809-0609
Funding Agency and Grant Number	Funding Agency Grant Number Science and Technology Plan of Qingdao 2019-3-027-YY
Corresponding Author	Lin-Li Qu, MD, PhD, Chief Doctor, Department of Medical Oncology, Qilu Hospital (Qingdao), Shandong University, No. 758 Hefei Road, Qingdao 266035, Shandong Province, China. qulinli2021@163.com
Key Words	Pleural mesothelioma; Immune checkpoint inhibitor; Next-generation Sequencing; Immune related pneumonia; Immunotherapy rechallenge; Case report
Core Tip	A patient with stage IIIB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy, and achieved partial response after four cycles, with progression-free survival of 5 mo.
Publish Date	2022-08-01 09:20
Citation	Xuan TT, Li GY, Meng SB, Wang ZM, Qu LL. Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. World J Clin Cases 2022; 10(23): 8284-8290
URL	https://www.wjgnet.com/2307-8960/full/v10/i23/8284.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i23.8284

Full Article (PDF)	WJCC-10-8284.pdf
Full Article (Word)	WJCC-10-8284.docx
Manuscript File	75093_Auto_Edited-LJH-LS.docx
Answering Reviewers	75093-Answering reviewers.pdf
Audio Core Tip	75093-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	75093-Conflict-of-interest statement.pdf
Copyright License Agreement	75093-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	75093-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	75093-Language certificate.pdf
Peer-review Report	75093-Peer-review(s).pdf
Scientific Misconduct Check	75093-Bing-Liu JH-2.jpg
Scientific Misconduct Check	75093-CrossCheck.jpg
Scientific Editor Work List	75093-Scientific editor work list.pdf
CrossCheck Report	75093-CrossCheck report.pdf